El winner of the Nobel Prize in Physiology and Medicine in 1996, Peter C. Doherty, resalt the efficacy of the Sputnik V vaccine against the coronavirus. Asimismo, afirm that the possible modifications to the dose ante the new variants of the virus do not cause failures in its creators.
In statements to the Russian news agency TASS, Doherty removes the use of viral vectors in the manufacture of the pharma developed by the Gamaleya Center.
“The efficiency of the Sputnik V -ms vacancy is 90% – it’s very good, and breathable, Russia has a long history of the development of vacancies. The strategy for the use of adenovirus vectors is well known, and is, according to its understanding, used in Sputnik. For that matter, if the virus changes significantly as a result of the mutation, the creators of the vaccine tend to correct “a little bit of the drug, but it will not be difficult,” said the specialist.
Die Lancet-publiek results from the vaccine rusa: its efficiency is 91.6%
Segn an intermediate analysis of phase 3 of the clinical trials, which was published on March 2 in the medical issue The Lancet, the vaccine rusa Sputnik V against the coronavirus has a general efficacy of 91.6%.
The publication shows that in dichos ensayos, 21,977 adults participated, that between September 7 and November 24, 2020, there will be a series of vacancies in the evacuation group (16,501 people) and placebo (5,746).
A total of 19,866 volunteers received the necessary doses for the immunization, and between them, confirmed only 78 cases of Covid-19.